|
May 5
|
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
|
|
May 5
|
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results
|
|
May 5
|
AI specialist Recursion trims pipeline in latest shakeup
|
|
May 5
|
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 5
|
Recursion Pharmaceuticals: Q1 Earnings Snapshot
|
|
May 5
|
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
|
|
May 4
|
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
|
|
Apr 29
|
Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)?
|
|
Apr 28
|
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Apr 25
|
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
|
|
Apr 23
|
3 Monster Stocks to Hold for the Next 10 Years
|
|
Apr 23
|
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
|
|
Apr 21
|
Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know
|
|
Apr 9
|
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
|
|
Apr 9
|
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
|
|
Apr 8
|
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
|
|
Apr 6
|
Recursion Pharmaceuticals (NasdaqGS:RXRX) Sees 27% Weekly Drop After Leadership Changes
|
|
Apr 3
|
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
|
|
Apr 3
|
Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market
|
|
Mar 31
|
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
|